Entropy Neurodynamics Limited Cash Flow Conversion Efficiency
Entropy Neurodynamics Limited cash flow conversion efficiency. Based on the latest financial reports, Entropy Neurodynamics Limited (ENP) has a cash flow conversion efficiency ratio of -0.110x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-809.59K ≈ $-572.83K USD) by net assets (AU$7.36 Million ≈ $5.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Entropy Neurodynamics Limited (2018–2026)
Cash flow conversion efficiency of Entropy Neurodynamics Limited from 2018 to 2026. This chart illustrates how Entropy Neurodynamics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Entropy Neurodynamics Limited stock price today for real-time trading data and today's change.
Entropy Neurodynamics Limited Cash Flow Conversion Ratio Explained
Entropy Neurodynamics Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Entropy Neurodynamics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entropy Neurodynamics Limited ranked by their cash flow conversion efficiency. Also see Entropy Neurodynamics Limited market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ocado Group PLC
LSE:OCDO
|
0.130x |
|
Remsons Industries Limited
NSE:REMSONSIND
|
0.250x |
|
Wellbiotec Co. Ltd.
KO:010600
|
-0.033x |
|
CLOUDR GROUP LTD.
F:H3L
|
N/A |
|
Omni-Lite Industries Canada Inc.
V:OML
|
0.030x |
|
Largo Resources Ltd
TO:LGO
|
-0.092x |
|
Willowglen MSC Bhd
KLSE:0008
|
-0.147x |
|
Kartal Yenilenebilir Enerji Uretim AS
IS:KARYE
|
-0.059x |
Annual Cash Flow Conversion Efficiency for Entropy Neurodynamics Limited (2018–2026)
The table below shows the annual cash flow conversion efficiency of Entropy Neurodynamics Limited from 2018 to 2026. Review ENP free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | AU$7.36 Million ≈ $5.21 Million |
AU$-3.41 Million ≈ $-2.41 Million |
-0.462x | +64.51% |
| 2025-06-30 | AU$5.96 Million ≈ $4.22 Million |
AU$-7.77 Million ≈ $-5.50 Million |
-1.303x | -22.03% |
| 2024-06-30 | AU$5.62 Million ≈ $3.98 Million |
AU$-6.00 Million ≈ $-4.25 Million |
-1.068x | -9.44% |
| 2023-06-30 | AU$4.13 Million ≈ $2.92 Million |
AU$-4.03 Million ≈ $-2.85 Million |
-0.975x | +0.01% |
| 2022-06-30 | AU$8.81 Million ≈ $6.23 Million |
AU$-8.59 Million ≈ $-6.08 Million |
-0.976x | -133.39% |
| 2021-06-30 | AU$18.87 Million ≈ $13.35 Million |
AU$-7.89 Million ≈ $-5.58 Million |
-0.418x | +68.78% |
| 2020-06-30 | AU$5.02 Million ≈ $3.55 Million |
AU$-6.72 Million ≈ $-4.75 Million |
-1.339x | -213.81% |
| 2019-06-30 | AU$5.12 Million ≈ $3.62 Million |
AU$-2.18 Million ≈ $-1.55 Million |
-0.427x | -103.30% |
| 2018-06-30 | AU$-7.27K ≈ $-5.14K |
AU$-93.93K ≈ $-66.46K |
12.924x | -- |
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more